ALX Oncology (ALXO) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ALX Oncology (ALXO) has outperformed Tiziana Life Sciences (TLSA) over the past year, losing 40.1% versus a loss of 50.7%. Over five years, TLSA leads with a -25.2% price change compared with -98.0% for ALXO. ALX Oncology is the larger company by market cap ($172.8 million vs $151.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | TLSA |
|---|---|---|
| Share price | $1.25 | $1.19 |
| Market cap | $172.85M | $151.44M |
| 1-day change | +5.93% | +5.31% |
| YTD return | +4.42% | -24.16% |
| 1-year return | -40.10% | -50.66% |
| 5-year return | -98.00% | -25.17% |
| EPS (TTM) | $-1.13 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $2.25 |
| 52-week low | $1.05 | $0.76 |
| Distance from 52-week high | -53.01% | -47.11% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +268.00% | +570.59% |
| Average volume | 1.04M | 720.16K |
| Shares outstanding | 138.28M | 127.26M |
| Employees | 48 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALXO has outperformed TLSA by 10.6 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
ALXO vs TLSA FAQ
Which is bigger, ALX Oncology or Tiziana Life Sciences?
ALX Oncology (ALXO) is larger, with a market capitalization of $172.85M compared with $151.44M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, ALXO or TLSA?
ALXO returned -40.10% over the past 12 months, compared with -50.66% for TLSA (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.